Antiproliferative immunosuppressants (Formulary)

AZATHIOPRINE

Important: Therapy notes

Azathioprine is also used in:

For advice on monitoring azathioprine refer to DMARD monitoring.

Important: Formulation and dosage details

Formulation:

Tablets 25mg, 50mg (specialist use only)

MYCOPHENOLATE MOFETIL

Important: Therapy notes

Be aware of the risk of pulmonary complications (bronchiectasis, pulmonary fibrosis) with mycophenolate.
MHRA advice: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients (February 2018) (www.gov.uk).
MHRA adviceMycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis (January 2015) (www.gov.uk).
Mycophenolate mofetil is also used in rheumatic disease (Drugs used in rheumatic diseases and gout).  For advice on monitoring mycophenolate mofetil refer to DMARD monitoring.

Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Capsules 250mg (specialist use only)

Important: Formulation and dosage details

Formulation:

Tablets 500mg (specialist use only)

Important: Formulation and dosage details

Formulation:

Oral suspension 1 gram/5mL (specialist use only)

Important: Formulation and dosage details

Formulation:

Powder for solution for infusion 500mg (specialist use only)

MYCOPHENOLIC ACID

Important: Therapy notes

  • Be aware of the risk of pulmonary complications (bronchiectasis, pulmonary fibrosis) with mycophenolate.
  • Mycophenolic acid is also used in rheumatic disease (Drugs used in rheumatic diseases and gout).
  • For advice on monitoring mycophenolic acid refer to DMARD monitoring.
    MHRA advice: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients (February 2018) (www.gov.uk).
    MHRA adviceMycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis (January 2015) (www.gov.uk).

    Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Enteric coated tablets (as mycophenolate sodium) (Ceptava®) 180mg, 360mg (specialist use only)

Editorial Information

Document Id: F290